The overall purpose was to improve the tumor targeting properties of radiolabeled biologicals by optimizing chemical parameters. This years research was centered on 2 projects. The first project was to modify a spherical polymer, generation 3 PAMAM dendrimer (G3, MW 6909) and use it as a universal carrier of radiolabels and biological molecules. Using 3-[I-125]iodobenzoate and norbiotinamidosuccinate as model molecules, we have optimized the conjugation level of these molecules to G3 and improved the whole-body clearance kinetics in mice by blocking the non-specific uptake of G3 to liver and kidney upon neutralization of the highly positive-charged G3 by succinylation. We further improved the clearance kinetics of the radiolabel by inserting a metabolizable linker, triglycine between the label and G3 to a level that can be useful for a therapy approach. This approach can be applied to synthesize At-211 labeled G3-biotin for an alpha emitter-therapy of cancer that is pretargeted with antibody-streptavidin. The second project was to label Annexin V (AV) with I-125, In-111, Y-86, and Tc-99m for the detection of apoptosis to monitor the progress of cancer therapy. Among these, Tc-99m and Y-86 labeled AV were of particular interest because of their ideal imaging properties.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL025001-01
Application #
6675308
Study Section
(NMRR)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cho, Hong-Jun; Lee, Sung-Jin; Park, Sung-Jun et al. (2016) Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging. J Control Release 237:177-184
Shin, In Soo; Jang, Beom-Su; Danthi, S Narasimhan et al. (2007) Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature. Bioconjug Chem 18:821-8
Jang, Beom-Su; Lim, Esther; Hee Park, Seung et al. (2007) Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice. Nucl Med Biol 34:363-70
Zhang, YuJian; Xiang, Laiman; Hassan, Raffit et al. (2006) Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 12:4695-701
Zhang, Meili; Yao, Zhengsheng; Zhang, Zhuo et al. (2006) The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 66:8227-32
Sato, Noriko; Hassan, Raffit; Axworthy, Donald B et al. (2005) Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 46:1201-9
Park, Luke S; Szajek, Lawrence P; Wong, Karen J et al. (2004) Semi-automated 86Y purification using a three-column system. Nucl Med Biol 31:297-301
Yao, Zhengsheng; Zhang, Meili; Garmestani, Kayhan et al. (2004) Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N"",N""'-tetraacetic acid-biotin. Clin Cancer Res 10:3137-46
Jeong, Jae Min; Lee, Jaetae; Paik, Chang Hum et al. (2004) Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. Arch Pharm Res 27:961-7
Sato, Noriko; Park, Chang W; Kim, Hyung-Sik et al. (2003) Synthesis of dendrimer-based biotin radiopharmaceuticals to enhance whole-body clearance. Nucl Med Biol 30:617-25

Showing the most recent 10 out of 12 publications